Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis

Current Opinion in Rheumatology

Volumn 20, Issue 1, 2008, Pages 23-28

  Saadoun, David ^b   Delluc, Aurelien ^b   Piette, Jean Charles ^b   Cacoub, Patrice ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

Antiviral therapy; Hepatitis C virus infection; Mixed cryoglobulinemia; Rituximab; Vasculitis

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB;

ALOPECIA; ANEMIA; ANTIVIRAL THERAPY; ARTERY THROMBOSIS; B LYMPHOCYTE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CRYOGLOBULINEMIA; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEVER; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY EMBOLISM; LIVER CELL CARCINOMA; LIVER FAILURE; MONOTHERAPY; MYALGIA; NEUTROPENIA; PANNICULITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; VIROTHERAPY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CRYOGLOBULINEMIA; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; VASCULITIS;

EID: 40349100130     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f1330c     Document Type: Review

References (59)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204-2212.
3. Sansonno D, De Vita S, Iacobelli AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160:3594-3601.
4. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91:2433-2442.
5. Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with nonhepatitis Cvirus-related mixed cryoglobulinemia. Arch Intern Med 2006; 166:2101-2108. Large monocentric study analysing the main features of non-HCV mixed cryoglobulinemia.
6. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multicentre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88:115-126.
7. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287-308.
8. Sene D, Ghillani-Dalbin P, Thibault V, et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 2004; 31:2199-2206.
9. Vallat L, Benhamou Y, Gutierrez M, et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004; 50:3668-3678.
10. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355-374.
11. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618-623.
12. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36:511-518.
13. Lidove O, Cacoub P, Hausfater P, et al. Cryoglobulinemia and hepatitis C: worsening of peripheral neuropathy after interferon alpha treatment. Gastroenterol Clin Biol 1999; 23:403-406.
14. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002; 25:909-913.
15. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
16. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90:3865-3873.
17. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751-756.
18. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84:3336-3343.
19. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27:2172-2178.
20. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28:2466-2473.
21. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46:3317-3326.
22. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42:632-638.
23. Cacoub P, Saadoun D, Limal N, et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52:911-915.
24. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006; 54:3696-3706. Large therapeutic study showing the long term benefit of standard or Peg-IFNα plus ribavirin in HCV-MC vasculitis.
25. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005; 21:653-662.
26. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137:571-580.
27. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77:2604-2613.
28. Mazzaro C, Carniello GS, Colle R, et al. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy. Ital J Gastroenterol Hepatol 1997; 29:343-350.
29. Mazzaro C, Little D, Pozzato G. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:2168-2170.
30. Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t (14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97:1555-1559.
31. Bauduer F. MALT non-Hodgkin's lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol 1996; 53:209.
32. Schott P, Pott C, Ramadori G, Hartmann H. Hepatitis C virus infection-associated noncryoglobulinaemic monoclonal IgMkappa gammopathy responsive to interferon-alpha treatment. J Hepatol 1998; 29:310-315.
33. Caramaschi P, Biasi D, Carletto A, et al. MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection. Recenti Prog Med 1999; 90:585-591.
34. Emens LA, Sulkowski MS. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:2168-2170.
35. Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int 1999; 14:288-293.
36. Patriarca F, Silvestri F, Fanin R, et al. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol 2001; 112:370-372.
37. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89-94.
38. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100:107-115.
39. Levine AM, Shimodaira S, Lai MM. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. N Engl J Med 2003; 349:2078-2079.
40. Gattoni A, Cecere A, Romano C, et al. Case report of a monoclonal gammopathy in a patient with chronic hepatitis: effects of beta-IFN treatment. Panminerva Med 1996; 38:175-178.
41. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18:1711-1716.
42. Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005; 105:74-76.
43. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468-473.
44. Ramos-Casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005; 14 (Suppl 1):s64-s72.
45. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54:650-671.
46. Hausfater P, Cacoub P, Assogba U, et al. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 2002; 91:627-630.
47. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101:3818-3826.
48. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62:1230-1233.
49. Catuogno M, Rezai S, Priori R, et al. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology 2005; 44:406.
50. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80:1560-1564.
51. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006; 33:1197-1198.
52. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003; 44:1951-1955.
53. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842-846.
54. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054-3061.
55. Cacoub P, Delluc A, Saadoun D, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: where do we stand? Ann Rheum Dis 2007 [Epub ahead of print]. Systematic review of published data with the use of rituximab in MC vasculitis.
56. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38:2308-2310.
57. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
58. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
59. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: Long term follow up and predictors of response. Ann Rheum Dis 2007; 66:1259-1262.